Short Interest in Senti Biosciences, Inc. (NASDAQ:SNTI) Decreases By 38.8%

Senti Biosciences, Inc. (NASDAQ:SNTI) was the target of a significant decline in short interest in the month of December. As of December 31st, there was short interest totalling 63,600 shares, a decline of 38.8% from the December 15th total of 103,900 shares. Approximately 2.2% of the shares of the company are short sold. Based on an average daily trading volume, of 2,230,000 shares, the short-interest ratio is currently 0.0 days.

Analyst Ratings Changes

Separately, Chardan Capital reissued a “buy” rating and issued a $10.00 price objective on shares of Senti Biosciences in a report on Monday, December 2nd.

Senti Biosciences Price Performance

Shares of SNTI traded up $0.38 during trading hours on Thursday, reaching $4.19. 457,682 shares of the company’s stock traded hands, compared to its average volume of 106,567. Senti Biosciences has a twelve month low of $1.52 and a twelve month high of $16.94. The business’s fifty day simple moving average is $3.93 and its two-hundred day simple moving average is $3.01. The firm has a market capitalization of $19.23 million, a price-to-earnings ratio of -0.27 and a beta of 2.42.

About Senti Biosciences

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.